Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.36 |
| ▸ | ENO1 | P06733 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459294 | 0.92 | ALDH1A1 (0.39) | ALDH1A1BTN3A1ENO1FDPS | |
| SCHEMBL2458691 | 0.84 | FDPS (0.53) | ALDH1A1BTN3A1GGPS1FDPSAGTR1 | |
| SCHEMBL2456571 | 0.83 | ALDH1A1 (0.42) | ALDH1A1BTN3A1ENO1FDPSPDE3A | |
| SCHEMBL9191973 | 0.83 | ALDH1A1 (0.40) | ALDH1A1BTN3A1ENO1GGPS1FDPS | |
| SCHEMBL2458967 | 0.81 | FDPS (0.42) | ALDH1A1BTN3A1ENO1FDPSPDE3A | |
| SCHEMBL9188504 | 0.80 | FDPS (0.41) | ALDH1A1BTN3A1ENO1FDPSPDE3A | |
| SCHEMBL2453750 | 0.79 | BTN3A1 (0.40) | ALDH1A1BTN3A1ENO1 | |
| SCHEMBL9192418 | 0.79 | ALDH1A1 (0.39) | ALDH1A1BTN3A1ENO1FDPS | |
| SCHEMBL2459326 | 0.76 | ALDH1A1 (0.48) | ALDH1A1BTN3A1ENO1 | |
| SCHEMBL9187310 | 0.74 | ALDH1A1 (0.39) | ALDH1A1ENO1GGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0416689-B1 | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | MERCK & CO INC (US) | 1995-11-29 | — | — | EP | claimed |
| US-5227506-A | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | MERCK & CO., INC. (US) | 1993-07-13 | — | — | US | claimed |
| EP-0416689-A2 | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | MERCK & CO. INC. (US) | 1991-03-13 | — | — | EP | claimed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| EP-0416689-B1 | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | MERCK & CO INC (US) | 1995-11-29 | — | — | EP | disclosed |
| US-5227506-A | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | MERCK & CO., INC. (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0416689-A2 | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors | MERCK & CO. INC. (US) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | ALDH1A1 3179/4885BTN3A1 2268/4885ENO1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.